Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women

Abstract

Summary The use of oestrogens in the treatment of genuine stress incontinence was assessed by a double‐blind prospective trial in 36 postmenopausal women with genuine stress incontinence who received 3 months of cyclical treatment with either piperazine oestrone sulphate or a matching placebo. Patients were assessed subjectively and objectively before and after treatment by 7‐day bladder charts, urethral pressure profiles (UPP), the Urilos nappy test, vaginal cytology and hormone assays (plasma oestrogens and gonadotrophins). There was no statistical difference in the subjective response to treatment between the two groups. After 6 weeks of treatment there was a greater reduction in the number of pad changes/24 h in the oestrogen‐treated patients that approached statistical significance but, because of a marked response in the placebo group, this difference was not significant after 3 months of treatment. There were also no significant differences between the two groups with respect to the UPP or Urilos measurements but the vaginal cytology and hormone profiles were significantly affected by oestrogens. In view of the possible risks of oestrogen therapy its use in genuine stress incontinence is limited.

The feasibility of urethral color ultrasound imaging in the diagnosis of female intrinsic sphincter deficiency: preliminary results

“…2,11 In clinical practice, however, the reported e ects of estrogen treatment, in terms of cure rates and urethral pro®le measurements, are con¯icting. 3,4,12,13 These aspects con®rm, as is known, that UPP is of limited practical value in studying continence or in the follow-up of incontinent patients undergoing estrogen therapy.…”

Quality of Life and Menopause: The Role of Estrogen

“…70 Although a few studies employing objective measures of stress urinary incontinence have yielded disappointing results, 70,71 subjective improvement with estrogen therapy has been reported, and several studies have demonstrated symptomatic relief of urinary complaints following HRT. For example, Raz et al 72 reported that a majority of their subjects had increased maximum urethral pressures with CEE (2.5 mg/day), and Walter et al 73 reported decreased objective measures of urine loss with estriol therapy.…”

Gynecologic Problems in Elderly Women and Results of Gynecologic Cancer Screening

“…11,12 Üriner inkontinans, yaşlanma ile birlikte sıklığı artan önemli geriatrik sendromlardan biridir. Toplumda yaşayan 60 yaş ve üzerindeki hastalarda prevalans %8-18 arasında iken, kadınlarda erkeklere nazaran 2 kat daha fazla görülmektedir.…”